Actively Recruiting
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Led by University Hospital, Angers · Updated on 2026-03-11
206
Participants Needed
14
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Angers
Lead Sponsor
U
Université Paris Cité
Collaborating Sponsor
AI-Summary
What this Trial Is About
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.
CONDITIONS
Official Title
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) according to European Association criteria or histologically confirmed
- No prior intra-arterial treatment for HCC or iCCA; previous non-intra-arterial treatments allowed
- If treatment proposed at Multidisciplinary Consultation Meeting (RCP): patient with Child-Pugh score less than B8
- Single or multiple HCC without lobar or trunk portal obstruction
- No bile duct dilatation
- For radioembolization proposed at RCP: no trunk portal tumor invasion and uni-lobar tumor invasion (except for centrohepatic iCCA)
- Total bilirubin less than 20 mg/l (or 35 µmol/L)
- Patient affiliated with or benefiting from a social security scheme
- Patient has signed informed consent form
You will not qualify if you...
- Technical contraindications or expected technical difficulties
- Planned combined same-day treatments at index procedure (e.g., TACE with percutaneous ablation) not allowed
- Chronic renal insufficiency with clearance less than 30 ml/min
- Known allergy to contrast agent or chemotherapy
- Inability to participate in outpatient care (including inability to understand instructions, lack of phone access, no responsible adult for first night after discharge, or inability to access urgent care timely)
- Previously included in this study
- Psychological, social, family, or geographical reasons preventing regular monitoring or follow-up
- Severe uncontrolled clinical conditions or infections
- Pregnant, breastfeeding, or recently given birth
- Person deprived of liberty by judicial or administrative decision
- Person under compulsory psychiatric care
- Person under legal protection
- Person unable to give consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
University hospital of Amiens
Amiens, France, 80054
Not Yet Recruiting
2
University hospital of Angers
Angers, France, 49933
Actively Recruiting
3
University hospital of Besançon
Besançon, France, 25030
Actively Recruiting
4
Hospital of Avicennes (AP-HP)
Bobigny, France
Not Yet Recruiting
5
University hospital of Brest
Brest, France, 29609
Not Yet Recruiting
6
Hospital of Beaujon (AP-HP)
Clichy, France, 92110
Actively Recruiting
7
Hospital of Vendée
La Roche-sur-Yon, France, 85925
Actively Recruiting
8
University hospital of Grenoble-Alpes
La Tronche, France, 38700
Not Yet Recruiting
9
University hospital of Montpellier
Montpellier, France, 34090
Not Yet Recruiting
10
University hospital of Nice
Nice, France, 06202
Actively Recruiting
11
Hospital of Pitié-Salpétrière (AP-HP)
Paris, France, 75013
Actively Recruiting
12
Hospital of Cochin (AP-HP)
Paris, France, 75014
Actively Recruiting
13
Univesity hospital of Bordeaux
Pessac, France, 33607
Not Yet Recruiting
14
Institut Gustave Roussy (IGR)
Villejuif, France, 94805
Actively Recruiting
Research Team
C
Christophe AUBE, Pr
CONTACT
S
Sandra MERZEAU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here